William Blair Starts aTyr Pharma (LIFE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St futures gain on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Bernstein raises server shipment forecast as AI infrastructure spending grows
- Supernus and Indivior agree to all-stock merger of equals
- Curium to acquire Lantheus in deal valued at up to $8 billion
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Citi Starts aTyr Pharma (LIFE) at Buy
June 1, 2015 8:04 AM EDTCiti initiated coverage on aTyr Pharma (NASDAQ: LIFE) with a Buy rating and a price target of $32.00.
For an analyst ratings summary and ratings history on aTyr Pharma click here. For more ratings news on aTyr Pharma click here.
Shares of aTyr Pharma closed at $22.89 yesterday.
... MoreJPMorgan Starts aTyr Pharma (LIFE) at Overweight
June 1, 2015 6:57 AM EDTJPMorgan initiated coverage on aTyr Pharma (NASDAQ: LIFE) with an Overweight rating and a price target of $42.00.
For an analyst ratings summary and ratings history on Life Technologies click here. For more ratings news on Life Technologies click here.
Shares of Life Technologies closed at $22.89 yesterday.
... MoreUPDATE: BMO Capital Starts aTyr Pharma (LIFE) at Outperform
June 1, 2015 6:34 AM EDT(Updated - June 1, 2015 7:03 AM EDT)
BMO Capital initiates coverage on aTyr Pharma (NASDAQ: LIFE) with a Outperform rating and a price target of $42.00.
Analyst Jim Birchenough commented, "Our favorable rating and outlook is supported by the company's identification of, and proprietary dominance in, the area of Physiocrine... More
